mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.021 |
0.5 |
mRNA |
BRD-K34099515 |
CTRPv2 |
pan-cancer |
AAC |
0.048 |
0.5 |
mRNA |
BRD-K27188169:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.032 |
0.5 |
mRNA |
BRD-K34222889 |
CTRPv2 |
pan-cancer |
AAC |
0.019 |
0.5 |
mRNA |
JW-480 |
CTRPv2 |
pan-cancer |
AAC |
-0.023 |
0.5 |
mRNA |
Dasatinib |
CTRPv2 |
pan-cancer |
AAC |
-0.022 |
0.5 |
mRNA |
Erlotinib |
CTRPv2 |
pan-cancer |
AAC |
-0.021 |
0.5 |
mRNA |
BRD-K63431240 |
CTRPv2 |
pan-cancer |
AAC |
-0.021 |
0.5 |
mRNA |
piperlongumine:MST-312 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.021 |
0.5 |
mRNA |
NSC95397 |
CTRPv2 |
pan-cancer |
AAC |
0.019 |
0.6 |